G E Meza-Reyes, J Cymet-Ramírez, R Esquivel-Gómez, Martínez A del Campo-Sánchez, M A E Martínez-Guzmán, F Espinosa-Larrañaga, A Majluf-Cruz, R Torres-González, J C De la Fuente-Zuno, E Villalobos-Garduño, J V Méndez-Huerta, E Ibarra-Hirales, J F Valles-Figueroa, J M Aguilera-Zepeda, E Díaz-Borjón
Venous thromboembolic disease (VTED) is a public health problem worldwide. In the United States it causes 2 million annual cases. Its annual incidence is 1-2 cases per 1,000 individuals in the general population. It is a disease frequently associated with life threatening complications and its mortality rate is 1-5% of cases. Due to its high complication rate, its slow recovery, and the need for prolonged disability, it is considered as a high-cost disease. VTED may occur in both surgical and medical patients; the known associated risk factors include prolonged rest, active cancer, congestive heart failure, atrial fibrillation, and stroke, among the major medical conditions...
July 2011: Acta Ortopédica Mexicana